6 May 2026
BIOPHARMA CREDIT PLC
(THE "COMPANY")
STATEMENT RE ALPHATEC PREPAYMENT
The Company notes the announcement released on 5 May 2026 by Alphatec Holdings, Inc. ("ATEC") regarding the prepayment in full of its US$200 million senior secured loan facility, of which the Company had an investment of US$35 million. The Company announced its US$35 million investment in the US$200 million senior secured loan facility to ATEC on 31 October 2024. The Company received a payment of US$37.1 million, comprised of US$35 million in return principal and US$2.1 million of prepayment fees and accrued interest. The Company earned a 14.91 per cent. gross internal rate of return and 11.93 per cent. net internal rate of return on its ATEC investment[1].
Enquiries:
BioPharma Credit plc
via MUFG Corporate Governance Limited
Company Secretary
+44 (0) 333 300 1932
Burson Buchanan
Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
[1] Past performance is not an indication of future performance. For more information as to how the Company calculates gross and net internal rates of return as used herein, please refer to the disclaimer on page 1 of the Company's investor presentation dated 20 April 2026, available on the Company's website (https://bpcruk.com/company-presentation-april-2026/).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
